Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG6H | ISIN: US45826J1051 | Ticker-Symbol: 38I
Tradegate
25.06.25 | 21:19
8,208 Euro
-0,27 % -0,022
1-Jahres-Chart
INTELLIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
INTELLIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,1608,36023:00
8,1308,26022:00

Aktuelle News zur INTELLIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INTELLIA THERAPEUTICS Aktie jetzt für 0€ handeln
15:34CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?12
MoIntellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress14
17.06.Intellia's three-year HAE treatment data shows durability, Citizens JMP says65
16.06.Assessing Intellia Therapeutics: Insights From 9 Financial Analysts52
16.06.Intellia's HAE gene therapy shows 98% attack reduction in three-year data23
15.06.Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ...190With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median...
► Artikel lesen
12.06.Intellia Therapeutics, Inc. - 8-K, Current Report6
11.06.Intellia Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans8
05.06.Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)170CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies...
► Artikel lesen
03.06.Canaccord Genuity lowers Intellia stock price target to $5449
31.05.Cathie Wood's ARK buys Intellia, 10x Genomics, sells Tesla stock175
29.05.Intellia filing spurs safety concerns over CRISPR drug45
29.05.Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course30
29.05.Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith42
29.05.Intellia stock holds $45 target despite AE concerns48
29.05.Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews15
29.05.Cantor maintains Intellia stock at $65 target despite trial concern22
29.05.H.C. Wainwright maintains $30 target on Intellia stock post-safety update11
29.05.Intellia stock tumbles on safety concerns12
29.05.Intellia slides after safety concern for Regeneron-partnered gene editing therapy20
Weiter >>
97 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,1,13